Vertex Pharmaceuticals | VRTX - Interest Expense On Debt


Vertex Pharmaceuticals reported $36M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amgen USD 653M 94.99B Sep/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
Incyte USD 605K 23K Sep/2026
Insmed USD 20.41M 1.57M Sep/2026
Ionis Pharmaceuticals USD 4M 14M Sep/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novartis USD 468M 6M Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 222M 65M Sep/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
United Therapeutics USD 2.9M 0 Sep/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026